As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs that efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Content to be used in accordance with local CPO guidelines
Alpelisib + fulvestrant in patients with PIK3CA-mutated, HR+, HER2– advanced breast cancer (ABC) who received chemotherapy or endocrine therapy (ET) as immediate prior treatment: BYLieve Cohort C primary results and exploratory biomarker analyses
Rugo HS
Presentation # PD13-05 – Spotlight Poster Discussion
December 10, 2021 | 7:00 AM CT
Impact of ESR1 mutations on endocrine therapy (ET) plus alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated, advanced breast cancer (ABC) who progressed on or after prior cyclin-dependent kinase inhibitor (CDK4/6i) therapy in the BYLieve trial
Turner N
Presentation # PD15-01 – Spotlight Poster Discussion
December 10, 2021 | 7:00 AM CT
Alpelisib + endocrine therapy (ET) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i): Biomarker analyses from the Phase II BYLieve study
Juric D
Presentation # P5-13-03 – Poster
December 10, 2021 | 7:00 AM CT
Alpelisib + fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + aromatase inhibitor (AI): 18-month follow-up of BYLieve Cohort A
Ciruelos EM
Presentation # P1-18-03 – Poster
December 08, 2021 | 7:00 AM CT
Effect of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy (≤6 mo or >6 mo) on alpelisib benefit in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve
Chia S
Presentation # P1-18-08 – Poster
December 08, 2021 | 7:00 AM CT
PIK3CA registry: A noninterventional, descriptive, retrospective cohort study of PIK3CA mutations in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC)
Rajadurai P
Presentation # P5-13-25 – Poster
December 10, 2021 | 7:00 AM CT
Endoresist: Prognostic and predictive gene profiles in endocrine-resistant breast cancers
Schagerholm C
Presentation # P1-07-07 – Poster
December 08, 2021 | 7:00 AM CT
Real-world natural history data among patients with PIK3CA mutant and PIK3CA wild-type advanced breast cancer
Razavi P
Presentation # P1-18-18 – Poster
December 08, 2021 | 7:00 AM CT
A real-world assessment of PIK3CA testing and alpelisib treatment patterns among metastatic breast cancer patients in a community oncology setting
O’Shaughnessy J
Presentation # P5-13-16 – Poster
December 10, 2021 | 7:00 AM CT
Ribociclib, everolimus, exemestane triplet therapy in HR+/HER2− advanced breast cancer after progression on a CDK4/6 inhibitor: Final efficacy, safety, and biomarker results from TRINITI-1
Hurvitz SA
Presentation # PD13-03 – Spotlight Poster Discussion
December 10, 2021 | 7:00 AM CT
Upregulation of immune response biomarkers by ribociclib plus endocrine therapy (ET) in paired tumor samples from phase I studies
Juric D
Presentation # P5-13-18 – Poster
December 10, 2021 | 7:00 AM CT
Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2- advanced breast cancer (ABC) across the MONALEESA (ML) studies
Prat A
Presentation # PD2-05 – Spotlight Poster Discussion
December 08, 2021 | 7:00 AM CT
Assessment of quality of life (QoL) in patients with metastatic breast cancer (MBC ) in clinical practice: A real-world multi-country survey
Cardoso F
Presentation # P4-12-03 – Poster
December 09, 2021 | 5:00 PM CT
Analysis of first-line (1L) patients (pts) with de novo disease vs late relapse and all pts with vs without chemotherapy (CT) in the MONALEESA-3 (ML-3) trial
De Laurentiis M
Presentation # P1-18-11 – Poster
December 08, 2021 | 7:00 AM CT
Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2, -3, and -7 studies of ribociclib + endocrine therapy in patients with HR+/HER2- advanced breast cancer
Carey L
Presentation # GS2-00 – Oral
December 08, 2021 | 8:30 AM CT
Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2- breast cancer
O’Shaughnessy J
Presentation # GS2-01 – Oral
December 08, 2021 | 8:45 AM CT
Presurgical treatment with ribociclib and letrozole in patients with locally advanced breast cancer: The NEOLETRIB trial
Tekpli X
Presentation # OT2-19-01 – Poster
December 09, 2021 | 5:00 PM CT
Circulating tumor DNA (ctDNA) dynamics in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first line with ribociclib (R) and letrozole (L) in the BioItaLEE trial
Bianchini G
Presentation # GS3-07 – Oral
December 09, 2021 | 10:15 AM CT
